J.Safra Asset Management Corp Avidity Biosciences, Inc. Transaction History
J.Safra Asset Management Corp
- $1.54 Billion
- Q3 2025
A detailed history of J.Safra Asset Management Corp transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 63 shares of RNA stock, worth $3,087. This represents 0.0% of its overall portfolio holdings.
Number of Shares
63
Previous 8
687.5%
Holding current value
$3,087
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RNA
# of Institutions
249Shares Held
119MCall Options Held
340KPut Options Held
145K-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$530 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X010.8MShares$528 Million0.16% of portfolio
-
Rtw Investments, LP New York, NY9.62MShares$471 Million4.2% of portfolio
-
Wellington Management Group LLP Boston, MA9.25MShares$453 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.25MShares$453 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.55B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...